key: cord-0977280-cad5qkfd
authors: Carlin, Rebecca F.; Fischer, Avital M.; Pitkowsky, Zachary; Abel, Dori; Sewell, Taylor B.; Landau, Erika Grun; Caddle, Steve; Robbins-Milne, Laura; Boneparth, Alexis; Milner, Josh D.; Cheung, Eva W.; Zachariah, Philip; Stockwell, Melissa S.; Anderson, Brett R.; Gorelik, Mark
title: Discriminating MIS-C Requiring Treatment from Common Febrile Conditions in Outpatient Settings
date: 2020-10-13
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.10.013
sha: d567d1012de2f97e92ec1d69c29d9f9d5690adb9
doc_id: 977280
cord_uid: cad5qkfd

OBJECTIVES: To examine whether patients with multisystem inflammatory syndrome in children (MIS-C) demonstrated well-defined clinical features distinct from other febrile outpatients given the difficulties of seeing acute care visits during the SARS-CoV-2 pandemic and the risks associated with both over and underdiagnosis of MIS-C. STUDY DESIGN: This case-controlled study compared patients diagnosed with and treated for MIS-C at a large urban children’s hospital with patients evaluated for fever at outpatient acute care visits during the peak period of MIS-C. Symptomatology and available objective data were extracted. Comparisons were performed using t-tests with corrections for multiple comparisons, and multivariable logistic regression to obtain odds ratios. RESULTS: We identified 44 patients with MIS-C between April 16 and June 10, 2020. During the same period 181 pediatric patients were evaluated for febrile illnesses in participating outpatient clinics. MIS-C patients reported higher median Tmax (40 degrees C vs 38.9, P < .0001), and increased frequency of abdominal pain (OR 12.5, 95% CI [1.65-33.24]), neck pain (536.5, [2.23-129,029]), conjunctivitis (31.3, [4.6-212.8]), oral mucosal irritation (11.8, [1.4-99.4]), extremity swelling or rash (99.9, [5-1960]) and generalized rash (7.42, [1.6-33.2]). Patients with MIS-C demonstrated lower absolute lymphocyte (p<0.0001) and platelet counts (p<0.05) and higher C-reactive protein concentrations (p<0.001). CONCLUSIONS: Patients treated for MIS-C due to concern for potential cardiac injury show combinations of features distinct from other febrile patients seen in outpatient clinics during the same period.

swelling or rash (99.9, ) and generalized rash (7.42, [1. 6-33.2] ). Patients with MIS-C demonstrated lower absolute lymphocyte (p<0.0001) and platelet counts (p<0.05) and higher Creactive protein concentrations (p<0.001).

Conclusions: Patients treated for MIS-C due to concern for potential cardiac injury show combinations of features distinct from other febrile patients seen in outpatient clinics during the same period.

Multisystem inflammatory syndrome (MIS-C) is a novel inflammatory disease that emerged worldwide between April and May of 2020.(1-5) Characterized by fever and a broad array of signs and symptoms and frequently presenting with shock, a major morbidity associated with MIS-C is cardiac injury with cardiac dysfunction and occasionally with aneurysms.(6, 7) MIS-C has been temporally linked with SARS-CoV-2 infection, and appears to be related to a dysregulated immunologic response to this infection that occurs primarily in children. (8) Critical questions and challenges have emerged since the first descriptive reports of MIS-C.

First, we do not know if this is the 'tip of the iceberg' (9) and if admitted cases to date represent a small, but severe, fraction of a similar phenotype that was observed in the outpatient setting.

Second, we are confronted with the difficulty of discriminating patients with MIS-C requiring early referral for cardiac evaluation from the broad number of children coming to medical attention to primary care and other outpatient settings because of fever. Further amplifying the challenge, patients with MIS-C have presented with and without shock, and with and without features overlapping with Kawasaki disease and toxic shock syndrome. Neither the presence of shock nor KD features have been helpful in predicting cardiac complications, including aneurysms, cardiac inflammation and mechanical dysfunction. (5, 7, 9) Additionally, with the expansion of telehealth, the limited hours and capacity in pediatricians' offices and the reluctance of families to seek in-person visits in offices and emergency departments (ED), pediatricians often are evaluating patients remotely with fractured care from other urgent care or telemedicine services.

In recognition of these challenges, we analyzed outpatient records to determine whether clinical presentations of patients admitted and treated for MIS-C were similar or distinguishable from other febrile patients in our outpatient clinics. Given the broad nature of some diagnostic guidelines for MIS-C, our intention was to seek 'red-flags' to indicate need for requiring further referral and evaluation.

We retrospectively reviewed the charts of MIS-C patients presenting to a tertiary care hospital during the peak of MIS-C cases, and all sick-visit encounters for febrile patients at a subset of affiliated pediatric primary care clinics during the same period. Study staff ( reviewed each encounter of patients meeting inclusion criteria related to the febrile episode of interest.

To construct the MIS-C cohort, we reviewed the records of patients reported as possible MIS-C to the New York City Department of Health (NYC-DOH) by our institution from April 16 to June 10, 2020.(1) MIS-C patients were then defined as patients who were treated with corticosteroid and IVIG after consulting rheumatologists and infectious disease physicians determined cases as highly concerning for MIS-C. We identified KD patients who were assessed by the same consulting services at our institution, who were determined, based on American Heart Association 2017 guidelines (10) and clinical judgment to have focused symptoms only consistent with KD; these cases were excluded from most analysis. Our analysis focuses on symptoms reported at presentation for MIS-C case patients, and although outpatient records were J o u r n a l P r e -p r o o f not available for MIS-C cases, pertinent information from emergency department (ED) documentation was reviewed and used.

The febrile outpatient cohort was constructed using a comprehensive list of all acute outpatient visits to participating hospital-affiliated primary care clinics during the same time period.

Patients were included if they were brought for evaluation of a febrile illness. Because no patients with MIS-C were infants, patients under 12 months of age were excluded. A subset of the febrile outpatients were also evaluated after clinic visit in our ED for the same febrile illness.

These encounters were included as both part of the larger febrile outpatient group and as a separate subset ('ED group') for some analyses. Three children in the febrile outpatient group had more than one febrile episode during the study period with documented periods of wellness in between; for ease of interpretation, only the final febrile episode was included in the main analysis. All reviewed encounters included demographic data, reported symptomatology over the course of their illness up to the point of presentation, findings on examination, results of basic laboratory tests, suspected or confirmed exposure to SARS-CoV-2 and final documented diagnosis.

Historical clinical variables that were not documented as being present by providers were presumed negative. For purposes of analysis, each patient's febrile episode was represented as one clinical encounter. For patients with multiple encounters for the same illness, each visit was reviewed and all information through the last encounter was included in the patient's symptomatology. Objective data, including vital signs and laboratory test results, were captured as repeated measures if there were multiple outpatient or ED encounters/tests.

Fever was defined as a temperature of ≥38° Celsius. Maximum reported temperature was based on parental report. If a patient's chart documented reported fever but did not document a measured temperature, or the only measured temperature was <38º Celsius, the patient was deemed febrile for data analysis, but their maximum fever height was recorded as "subjective."

Clinical and demographic variables were described using summary statistics and compared using univariable analyses among febrile outpatients, febrile outpatients referred to the ED and patients with MIS-C. For temperature height and duration comparisons, student test was performed with false discovery analysis using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli, with Q = 1%. Each row was analyzed individually. For temperature comparisons for duration and height, second order polynomial curves were fitted to data points from all outpatients and patients referred to the ED, and all MIS-C patients, and 95% confidence interval bands were plotted. For patient characteristics associated with MIS-C, significance levels of <0.1 were tested in logistic regression via stepwise, forward procedure. Patient characteristics with significance levels <0.05 in multivariable analyses were retained in the final models. Models were tested for confounding and effect modification. In sensitivity analyses, we then repeated analyses, including the three patients with more than one febrile episode, and clustered standard errors for repeat patients. For collinear variables, adjusted R2 was used to determine variable inclusion. For odds ratios, a non-parsimonious logistic regression model without stepwise J o u r n a l P r e -p r o o f procedure utilizing all variables was done. Statistical analysis was performed using STATA v. 16 and figures/additional statistics using PRISM 8.3.

This study was approved by the Columbia University Irving Medical Center institutional review board. A waiver of informed consent was provided.

We identified 59 patients meeting NYC-DOH reportable criteria for possible MIS-C (11) who were admitted to our institution during the study time frame. Of these, 44 patients were diagnosed with and treated for MIS-C; 7 met criteria for only KD and were excluded. Overall, 181 control patients were identified with 184 separate febrile episodes. Of patients initially seen in ambulatory clinics, 23 patients also had ED visits.

The demographics of each group are described in Table I (Figure 1, A) and a higher total duration of fever reported at the time of seeking medical attention (5 days vs. 2 days, p<0.001) (Figure 1, B) than other febrile outpatients. Additionally, 42 febrile outpatient controls, and 1 who was referred to the ED, had fever which had resolved prior to medical attention. None of the patients in the MIS-C group had fever that resolved prior to treatment, including a patient who was only recognized to have MIS-C 15 days into his hospitalization and had persistent fevers during this entire period. 

A list of most common diagnoses for the febrile outpatients is presented in Table 2 (available at www.jpeds.com).

Of 181 febrile outpatients, most were seen as telehealth visits, which did not include laboratory testing; only patients referred to the ED, and in rare cases, patients seen in person in an outpatient clinic, had blood or urine testing performed. Therefore we only compared laboratory test results for the ED group's for MIS-C (Figure 4 

The majority of patients treated for MIS-C showed some evidence of end organ dysfunction in the form of shock and/or echocardiographic evidence of cardiac involvement or dysfunction (Table 3 ; available at www.jpeds.com).

We found a clear difference in presenting symptomatology and basic laboratory test findings in patients diagnosed and treated for MIS-C compared with febrile outpatients who received other diagnoses. We do not yet know the consequences of a missed diagnosis of MIS-C, but in a number of patient series (with the total number of patients described to date being under 1,000), the incidence of cardiac damage in the form of aneurysm is small but present, (approximately 8 -10%), and few patients have died. (2, 3, 5, 7, 11) At the same time, there is risk in over diagnosing and overtreating presumed MIS-C patients. Unpublished communications suggest that patients with other serious conditions, including malignancies, have been treated with corticosteroids and IVIG for presumed MIS-C prior to a correct diagnosis. Although patients presenting in shock are clearly distinct from than those presenting with low-grade fevers, "ruleout" MIS-C had to be considered for the majority of children coming to attention because of fever. The question of when to refer patients for full laboratory and cardiac evaluation plagued outpatient providers. Our study demonstrates some useful "red-flags". For instance, an older patient with high level and prolonged fever, rash, severe abdominal pain and neck pain or stiffness, with a history of suspected SARS-CoV-2 exposure, should be referred. A younger patient with a low-grade fever and upper respiratory congestion should have follow up but not further evaluation.

Difficulty clearly identifying MIS-C in a clinical setting extends to difficulty in studying and understanding the disease in a research setting. This issue was raised by Rowley, who noted that the "very broad case definition for MIS-C is of concern...because inclusion of children who have other conditions will skew results and obscure accurate conclusions."(12) Thus, we defined our MIS-C cohort for study as patients who received treatment not only after meeting suggested MIS-C criteria but also having evidence of potential cardiac involvement by either cardiac dysfunction on echocardiogram, coronary abnormalities, or sustained, progressive or markedly elevated ntBNP. Elevated ntBNP has been reported to be associated with cardiac dysfunction or cardiogenic shock in the context of MIS-C. (13, 14) However, it should be noted in our cohort that all 44 patients in the MIS-C cohort who were treated had abnormal ntBNP and only 56% had abnormal function on echocardiogram and 5% had coronary abnormalities. This emphasizes the non specific nature of ntBNP as a marker of cardiac dysfunction, but suggests it may have a role in prompting further cardiac evaluation for suspected MIS-C.

Our study has significant limitations. Perhaps most importantly, MIS-C cases were initially observed in the ED, whereas most controls were seen at outpatient telehealth visits. Although this presents some challenges to interpretation, two points are of particular importance. First, records from both groups were upon initial encounter with our healthcare system and thus, we Although KD and MIS-C can have overlapping features (9, 15, 16) , for our study, we excluded patients with clearly recognizable KD and no extended features as seen in MIS-C from formal comparisons. Findings in our KD patients were included to give readers the full view of the data.

Our data suggest that children who will require intervention for MIS-C are clinically distinguishable from other febrile children and that red flags can be sought and patients identified who will require further evaluation. Further long term study of children exposed to SARS-COV-J o u r n a l P r e -p r o o f 3/7 (43) 1 2 *7 patients admitted with prolonged fever did not have typical features of MIS-C (such as abdominal pain or neurologic features). These patients were treated following AHA Kawasaki disease criteria only. [10] **Nasopharyngeal SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) testing (Roche Cobas SARS-CoV-2 assay), and COVID-19 antibody testing (New York State Department of Health-approved combined assay for immunoglobulin M and G antibodies against SARS-CoV-2 spike trimer or nucleocapsid protein).

J o u r n a l P r e -p r o o f 

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Hyperinflammatory shock in children during COVID-19 pandemic

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. The Lancet

Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

Childhood Multisystem Inflammatory Syndrome -A New Challenge in the Pandemic

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

Multisystem Inflammatory Syndrome in Children in New York State

Diagnosing SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children

Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease?

Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features